EXV4.DE
iShares STOXX Europe 600 Health Care UCITS ETF (DE)
Europe
EQUITY
Passive
MANAGEMENT STYLE
€ 711.6 M
ASSETS UNDER MGMT
46 bp
EXPENSES
Fund Basics
| Inception date | Apr 25, 2001 |
| Regulation | UCITS |
| ISIN | DE000A0Q4R36 |
| Distributions | Quarterly |
| Currency | EUR |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ROCHE HOLDING AG-BR | 15.1 % |
| ASTRAZENECA PLC | 13.8 % |
| NOVARTIS AG | 13.7 % |
| NOVO NORDISK A/S-B | 9.3 % |
| SANOFI-AVENTIS | 5.2 % |
| ESSILOR INTERNATIONAL | 4.9 % |
| GSK PLC | 4.9 % |
| ARGEN-X SE | 2.5 % |
| LONZA GROUP AG-REG | 2.5 % |
| BAYER AG | 2.4 % |
Constituent Breakdown
| Number of holdings | 60 |
| Herfindahl-Hirschman Index | 814 |
| Wgt avg mkt cap (mns) | $127,745 |
| Large cap (>$10bn) | 93.1% |
| Mid cap ($2-10bn) | 2.3% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 96.5% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
SWITZERLAND | 36.5 % |
 |
BRITAIN | 22.1 % |
 |
DENMARK | 12.8 % |
 |
FRANCE | 11.0 % |
 |
GERMANY | 6.2 % |
 |
NETHERLANDS | 3.6 % |
 |
BELGIUM | 2.1 % |
 |
SWEDEN | 0.8 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 5.4% | 1.2% | 4.5% | 6.5% | 7.1% | 5.3% | 5.3% | 4.0% |
| Dividend Yield | 0.1% | 1.7% | 1.6% | 1.6% | 1.7% | 1.9% | 2.1% | 1.7% |
| Total Returns | 5.4% | 2.9% | 6.1% | 8.2% | 8.7% | 7.2% | 7.4% | 5.8% | Ann. Volatility | 15.4% | 19.1% | 16.6% | 15.5% | 15.2% | 15.7% | 16.3% | 17.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.03 | 0% |
| MSCI EAFE | 0.27 | 6% |
| MSCI Emg Mkts | 0.16 | 2% |
Liquidity Measures
| Avg. volume (000) | 10 |
| ADV traded (mns) | $1 |
| Turnover | 0.2% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $119.14 |
| Relative strength (RSI) | 57 |
| MACD/Signal | 0.87/1.13 |
| Bollinger Bands (Upper/Lower) | $123.10/$116.65 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. EXV4.DE |
Expenses vs. EXV4.DE |
ALTAR Score™ vs. EXV4.DE |
|---|---|---|---|---|
| ESIH.L | iShares MSCI Europe Health Care Sector UCITS ETF | 93.7% | -28 bp | +0.3% |
| XSDR.DE | Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | 64.9% | -29 bp | +0.2% |
| C030.DE | Amundi DJ Switzerland Titans 30 UCITS ETF Dist | 29.2% | -21 bp | -0.8% |
| XZEC.DE | Xtrackers Stoxx European Market Leaders UCITS ETF 1C | 26.4% | -21 bp | 0.0% |
| WHCS.AS | iShares MSCI World Health Care Sector Advanced UCITS ETF | 24.1% | -28 bp | 0.0% |
| WHCA.L | iShares MSCI World Health Care Sector Advanced UCITS ETF | 24.1% | -28 bp | -0.3% |
| WELS.DE | Amundi S&P World Health Care Screened UCITS ETF Acc | 24.0% | -28 bp | 0.0% |
| WELG.DE | Amundi S&P World Health Care Screened UCITS ETF Dist | 24.0% | -28 bp | -0.1% |
| XSMC.SW | Xtrackers Switzerland UCITS ETF 1C | 19.9% | -16 bp | -0.2% |
| XSMI.DE | Xtrackers Switzerland UCITS ETF 1D | 19.9% | -16 bp | -0.2% |
Risk and Returns: EXV4.DE vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (EUR)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/5/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.6%
ALTAR SCORE™
33rd
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 239 funds in the Europe Equity category with an average
ALTAR Score™ of 7.2% and a standard deviation
of 1.3%. EXV4.DE's ALTAR Score™ is approximately -0.4 standard
deviations above the category average. This places EXV4.DE in the 33rd percentile
among funds in the category.
Sell-Side Consensus
€125.41
PRICE TARGET
+10.1%
UPSIDE